Liberate Medical, a Crestwood, KY-based company which specializes in in the development of novel non-invasive neurostimulation devices, raised $6.2M in Series B funding.
The round was led by co-led by a strategic investor and Scientific Health Development.
The company intends to use the funds to support the pivotal clinical trial of the VentFree Respiratory Muscle Stimulator. The Series B funding will provide the resources to complete the PREVENT trial, in anticipation of FDA regulatory clearance and full commercial launch of VentFree.
Led by CEO Angus McLachlan, Liberate Medical is a medical device company that develops neuromuscular electrical stimulation technology to improve the quality and reduce the cost of care for patients with pulmonary disorders. Its VentFree Respiratory Muscle Stimulator is a non-invasive, breath synchronized, neuromuscular electrical stimulator intended to prevent expiratory muscle atrophy in mechanically ventilated patients.
RELATED: Berry Health raises $1.6m pre-seed funding co-led by Lightspeed and General Catalyst
